Brandtree

Alnylam: brands it owns and its ownership tree

Alnylam (NASDAQ: ALNY) is a publicly listed company headquartered in Cambridge, United States that owns 4 consumer brands.[1]

Alnylam is a US biotechnology company that develops RNA interference medicines. Its 2025 Form 10-K reports sales of Amvuttra, Onpattro, Givlaari and Oxlumo.

Company facts

Legal name
Alnylam Pharmaceuticals, Inc.
Headquarters
🇺🇸 Cambridge, United States
Type
publicly listed company · all publicly listed company owners
Founded
2002
Tickers
NASDAQ: ALNY
Identifiers
SEC CIK 0001178670
Last verified
· 1 sources

Brands Alnylam owns

4 brands in 1 category.

Drug makers (4)

  • Amvuttra

    Biotechnology · 🇺🇸 United States

  • Givlaari

    Biotechnology · 🇺🇸 United States

  • Onpattro

    Biotechnology · 🇺🇸 United States

  • Oxlumo

    Biotechnology · 🇺🇸 United States

Full list of 4 brands with sources · Interactive ownership tree

Ownership structure

No company is recorded as controlling Alnylam.

Who owns the shares of Alnylam

Holders of more than 5% of the voting shares, as listed in Alnylam's proxy statement filed 6 April 2026. Shareholdings change daily; this is the position the filing reports.

HolderSharesShare of class
FMR LLC16,834,09512.7%
Capital World Investors16,398,88912.4%
The Vanguard Group13,056,6059.8%
BlackRock, Inc.8,546,5576.4%
Capital Research Global Investors6,968,5135.3%

Financials and filings

Alnylam financial history

Headline figures from Alnylam's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $492.9m to $3.71bn, an average of 49.8% a year (calculated).

Fiscal year endedRevenueOperating incomeOperating marginNet incomeTotal assetsLong-term debtFiling
$3.71bn $501.6m 13.5% $313.7m $4.97bn — 10-K
$2.25bn $-176,885,000 -7.9% $-278,157,000 $4.24bn — 10-K
$1.83bn $-282,175,000 -15.4% $-440,242,000 $3.83bn — 10-K
$1.04bn $-785,072,000 -75.7% $-1,131,156,000 $3.55bn — 10-K
$844.3m $-708,652,000 -83.9% $-852,824,000 $3.64bn — 10-K
$492.9m $-828,438,000 -168.1% $-858,281,000 $3.41bn — 10-K

Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.

Alnylam SEC filings

The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.

Annual reports

Proxy statements

Recent current and quarterly reports

FiledFormWhat it declares
8-KDeparture or appointment of directors or officers; Other events
10-QQuarterly report
8-KResults of operations and financial condition
10-QQuarterly report
8-KResults of operations and financial condition
8-KDeparture or appointment of directors or officers; Results of a shareholder vote
10-QQuarterly report
8-KResults of operations and financial condition
8-KDeparture or appointment of directors or officers
8-KResults of operations and financial condition
8-KResults of operations and financial condition
8-KOther events
8-KDeparture or appointment of directors or officers
8-KResults of operations and financial condition

Alnylam in the global legal-entity registry

The Global Legal Entity Identifier Foundation (GLEIF) keeps an open register of legal entities. Each entity reports its own parents. We show it as a cross-check on the ownership recorded on this page, which is built from filings.

Legal entity identifier (LEI)
529900S3ZI14OWRJII50
Registered name
Alnylam Pharmaceuticals, Inc. (US)
Registration status
Issued · record updated 2 July 2026
Parent
None named: it reports that it has no parent that consolidates its accounts.
Retrieved
· GLEIF record (JSON)

Frequently asked questions

What brands does Alnylam own?

Alnylam owns 4 consumer brands tracked here, including Amvuttra, Givlaari, Onpattro and Oxlumo.

Is Alnylam an American company?

Yes. Alnylam is headquartered in Cambridge, United States and was founded in 2002.

Who owns Alnylam?

Alnylam is a publicly listed company owned by its shareholders; it trades as ALNY on the NASDAQ.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Alnylam Pharmaceuticals, Inc. Annual Report on Form 10-K filed 2026-02-12 — SEC EDGAR, SEC Form 10-K, published 12 February 2026; retrieved 8 November 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.